Envoy Medical, Inc.COCHEarnings & Financial Report
Envoy Medical, Inc. is a medical technology firm specializing in developing and commercializing advanced implantable hearing solutions for sensorineural hearing loss patients. Its core products include fully implanted middle ear hearing devices, with primary markets across North America and Europe, serving users who gain limited benefit from conventional external hearing aids.
COCH Q4 FY2025 Key Financial Metrics
Revenue
$75.0K
Gross Profit
$-136.0K
Operating Profit
$-6.4M
Net Profit
$-6.6M
Gross Margin
-181.3%
Operating Margin
-8513.3%
Net Margin
-8781.3%
YoY Growth
78.6%
EPS
$-0.27
Envoy Medical, Inc. Q4 FY2025 Financial Summary
Envoy Medical, Inc. reported revenue of $75.0K (up 78.6% YoY) for Q4 FY2025, with a net profit of $-6.6M (down 42.6% YoY) (-8781.3% margin). Cost of goods sold was $211.0K, operating expenses totaled $6.2M.
Key Financial Metrics
| Total Revenue | $75.0K |
|---|---|
| Net Profit | $-6.6M |
| Gross Margin | -181.3% |
| Operating Margin | -8513.3% |
| Report Period | Q4 FY2025 |
Envoy Medical, Inc. Annual Revenue by Year
Envoy Medical, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $241.0K).
Envoy Medical, Inc. Quarterly Revenue & Net Profit History
Envoy Medical, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $75.0K | +78.6% | $-6.6M | -8781.3% |
| Q3 FY2025 | $42.0K | -25.0% | $-6.5M | -15433.3% |
| Q2 FY2025 | $78.0K | +14.7% | $-5.7M | -7294.9% |
| Q1 FY2025 | $46.0K | -22.0% | $-5.0M | -10865.2% |
| Q4 FY2024 | $42.0K | -55.8% | $-4.6M | -10995.2% |
| Q3 FY2024 | $56.0K | -30.0% | $-6.0M | -10642.9% |
| Q2 FY2024 | $68.0K | +7.9% | $-3.9M | -5804.4% |
| Q1 FY2024 | $59.0K | -24.4% | $-6.3M | -10627.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $59000 | $68000 | $56000 | $42000 | $46000 | $78000 | $42000 | $75000 |
| YoY Growth | -24.4% | 7.9% | -30.0% | -55.8% | -22.0% | 14.7% | -25.0% | 78.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $8.5M | $6.7M | $9.4M | $11.5M | $10.4M | $9.9M | $8.2M | $8.6M |
| Liabilities | $15.9M | $19.1M | $27.9M | $30.4M | $34.6M | $39.8M | $15.7M | $20.3M |
| Equity | $-7.4M | $-12.4M | $-18.5M | $-18.8M | $-24.2M | $-29.9M | $-7.7M | $-12.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-5.6M | $-4.6M | $-2.6M | $-5.1M | $-3.7M | $-4.5M | $-4.3M | $-5.7M |